UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced positive top-line Phase II study results for its novel ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, ...

Participant Characteristics: Blinded baseline data aligns with the target population identified in the Phase 2b UC study. Safety Monitoring: No new safety signals observed in the latest Data ...

The Wee1 inhibitor adavosertib shows activity in recurrent uterine serous carcinoma, but the drug’s tolerability remains a ...

The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative ... s potential efficacy and safety profile as we advance through ...

The study design included a 24-week placebo-controlled phase, followed by 24 weeks of active treatment and a 12-week safety follow-up period. Participants who consented received an additional 2 ...

Participant Characteristics: Blinded baseline data aligns with the target population identified in the Phase 2b UC study. Safety Monitoring: No new safety signals observed in the latest Data Safety ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...